Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand – CNBC
Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand CNBCLilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio Eli LillyEli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales Yahoo FinanceLilly Raises Sales Guidance, Widening Its Lead in Obesity Market BloombergEli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound WSJ
সূত্র: মূল সংবাদসূত্র
